top of page


Updated: Aug 23, 2021

In this issue of GOLD, we reveal the pharmaceutical industry’s key news stories from the past few months, covering the latest COVID-19 vaccine developments, FDA and European Commission approvals, and major collaborations.

26 January

'The 2021 Access to Medicine Index' is published, with GSK ranked in first place

28 January

Novavax’s COVID-19 vaccine shows 89% efficacy in UK Phase 3 trial

03 February

GSK and CureVac partner to develop next generation mRNA COVID-19 vaccines

17 February

The European Commission purchases 150 million doses of Moderna’s COVID-19 vaccine

09 January

Bayer announce their collaboration with UK-based Exscientia to accelerate the potential of AI in cardiovascular and oncology drug discovery

25 February

Merck & Co. places an offer to acquire Pandion Therapeutics in $1.85 billion deal

01 March

Boehringer Ingelheim and Gubra partner to identify peptides to treat obesity

16 January

HIV infections among gay and bisexual men in the UK are reported to have fallen by 71%, following the launch of PrEP, a pill that prevents HIV infection

04 March

Novartis signs initial agreement to manufacture CureVac’s COVID-19 vaccine

16 March

Roche launches SARS-CoV-2 variant test to monitor COVID-19 mutations

22 March

Takeda and Evotec form alliance for strategic RNA targeting drug discovery and development

27 March

FDA approves BMS and bluebird bio’s Abecma, the first cell-based gene therapy for patients with multiple myeloma

29 March

Johnson & Johnson announces agreement with African Union for ≤400 million doses of its COVID-19 vaccine

30 March

The European Commission approve Roche’s Evrysdi, the first at-home treatment for spinal muscular atrophy

bottom of page